The Native Antigen Company, part of LGC Clinical Diagnostics, has won ‘The Best COVID-19 Responder’ at OBN 2020 Awards, recognising the company’s outstanding contribution to the fight against COVID-19.
The Native Antigen Company has utilised its expertise in developing high-quality reagents to play a major role in the global response to SARS-CoV-2. In February 2020, The Native Antigen Company was among the first companies to make SARS-CoV-2 antigens commercially available for researchers developing diagnostics and vaccines to fight the pandemic. In April last year, it partnered with OXGENE to scale COVID-19 antigen production to support the development of diagnostic kits and vaccine development. Following this, the Company introduced a range of SARS-CoV-2-specific antibodies and a neutralisation assay development kit, which enables the identification and assessment of antibodies for SARS-CoV-2 variants for diagnostic, vaccine and therapeutic research.
It now offers a growing range of reagents to support research into the coronaviruses, including antigens, antibodies, receptors, enzymes and custom development services, further expanding its offering to support research and development of technology to fight COVID-19.
The OBN awards seek to commend companies at all stages of development, recognising inspirational leadership, exciting innovation, novel and inspiring approaches to unmet clinical need, outstanding company progression and the delivery of real-life tangible results.
Dr Nick Roesen, Chief Operating Officer, The Native Antigen Company (pictured left reiving the award) said: “To be recognised by this prestigious award is testament to our hard work and progress over the past year. Central to stemming the transmission of disease is the availability of high-quality reagents for diagnosis, antibody testing and the development of safe and effective vaccines. Our commitment to supplying vital reagents, especially in such challenging and unprecedented times, is a proud achievement. We look forward to continuing this work to expand our support for infectious disease research.”